EntryPoint Capital’s 4D Molecular Therapeutics FDMT Stock Holding History

EntryPoint Capital’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-21,602	Closed	-$201K	–	848
2026 Q1	$201K	Sell	21,602 -722	-3%	-$6.28K	0.06%	642
2025 Q4	$167K	Buy	+22,324	New	+$226K	0.07%	578
2025 Q1	–	Sell	-55,539	Closed	-$309K	–	756
2024 Q4	$309K	Buy	55,539 +31,020	+127%	+$243K	0.13%	353
2024 Q3	$265K	Buy	24,519 +17,254	+237%	+$286K	0.15%	301
2024 Q2	$152K	Buy	+7,265	New	+$182K	0.07%	560

Other funds holding FDMT

Jupiter Topco New York $245B AUM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

EntryPoint Capital's FDMT Position: Q2 2026 in Review

EntryPoint Capital sold out of 4D Molecular Therapeutics (FDMT) in Q2 2026, closing a stake of 21,602 shares — an estimated $201K sold.

EntryPoint Capital first reported a position in FDMT in Q2 2024 and held it in 5 quarters. The position peaked at $309K in Q4 2024. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

EntryPoint Capital reported no remaining 4D Molecular Therapeutics position as of Q2 2026 after selling out during the quarter.
EntryPoint Capital sold 21,602 4D Molecular Therapeutics shares in Q2 2026, an estimated $201K.
EntryPoint Capital first reported a position in 4D Molecular Therapeutics in Q2 2024 and held it in 5 quarters.
EntryPoint Capital's 4D Molecular Therapeutics position peaked at $309K in Q4 2024.
158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.